Cara Therapeutics

3 followers


Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Industries

Employees

51-200

Links


Org chart

Christopher Posner
CEO, President & Director
Collapse
Ryan Maynard
Chief Financial Officer
Frédérique Menzaghi
Chief Scientific Officer, SVP Research & Development
Scott Terrillion
General Counsel, Secretary & Chief Compliance Officer
Eric Vandal
SVP, Commercial
Stephen O’Connor
Vice President CMC Technical Operations
Rene Barron
Executive Director, HR

Board & advisors